Loading...
•
Dec 31, 2023
Aquestive Q4 2023 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a progress update on the key 2024 objectives.
Key Takeaways
Aquestive Therapeutics reported a strong finish to 2023 with double-digit base revenue growth and an improved balance sheet. The company is focused on progressing Anaphylm to a US filing, expanding its revenue base, and advancing its pipeline assets.
Total revenues were $13.2 million in the fourth quarter 2023, compared to $10.7 million in the fourth quarter 2022, an increase of 24%.
Manufacture and supply revenue increased by 23%, or $2.1 million.
Aquestive’s net loss for the fourth quarter 2023 was $8.1 million, or $0.12 loss per share.
Non-GAAP adjusted EBITDA loss was $2.8 million in the fourth quarter 2023, compared to a $9.6 million loss in the fourth quarter 2022.
Forward Guidance
Aquestive is providing its full year 2024 financial outlook. The Company expects: GuidanceTotal revenue (in millions)$48 to $51Non-GAAP adjusted EBITDA loss (in millions)$22 to $26
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...